CORRECTION article

Front. Immunol., 23 January 2024

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1331003

Corrigendum: Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models

  • 1. DermoLab, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy

  • 2. PinCell s.r.l., Milan, Italy

  • 3. Lübeck Institute of Experimental Dermatology, University of Lübeck, Lubeck, Germany

In the published article, there was an error in the author list, and author Christoph M. Hammers was erroneously excluded. The corrected author list appears below.

Roberta Lotti1,2, Jennifer E. Hundt3, Ralf J. Ludwig3, Christoph M. Hammers3, Brydon Bennett2, Antonino Amato2, Alessandra Marconi1,2†, Carlo Pincelli1,2†

A correction has been made to Author contributions.

This sentence previously stated:

“RL, BB, JH, AM, and CP contributed to conception and design of the study. RL and JH performed experiments and data collection. JH and RL analysed data. RL performed the statistical analysis. RL, AM, CP, AA, JH and RJL have discussed and interpreted the data. RL and CP wrote the first draft of the manuscript. RJL, BB, AA and AM wrote sections of the manuscript. All authors contributed to the article and approved the submitted version.”

The corrected sentence appears below:

“RL, BB, JH, AM, and CP contributed to conception and design of the study. RL and JH performed experiments and data collection. JH and RL analysed data. CMH provided scFv. RL performed the statistical analysis. RL, AM, CP, AA, JH and RJL have discussed and interpreted the data. RL and CP wrote the first draft of the manuscript. RJL, BB, AA and AM wrote sections of the manuscript. All authors contributed to the article and approved the submitted version.”

The Acknowledgments, which previously stated “We thank Christoph M. Hammers from Lübeck Institute of Experimental Dermatology for providing scFv.”, has also been deleted.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

pemphigus, FasL, acantholysis, drug development, ex-vivo model

Citation

Lotti R, Hundt JE, Ludwig RJ, Hammers CM, Bennett B, Amato A, Marconi A and Pincelli C (2024) Corrigendum: Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models. Front. Immunol. 15:1331003. doi: 10.3389/fimmu.2024.1331003

Received

31 October 2023

Accepted

15 January 2024

Published

23 January 2024

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

15 - 2024

Updates

Copyright

*Correspondence: Roberta Lotti, ;

†These authors share senior authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics